LYMPHOPROLIFERATIVE DISORDERS

This study tests if a stem cell transplant can cure people with severe immune system diseases that haven't responded to standard treatments. Participants aged 4-69 will receive donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently f…

This study tests whether a stem cell transplant from a healthy donor can control peripheral T-cell lymphoma that has not responded to standard treatments. Participants receive antibody therapy or chemotherapy before the transplant to prepare their body, then stay in the hospital …

This study is for people with a type of blood cancer called T-cell lymphoma that has returned or not improved after standard treatments. Researchers want to see if the drug pacritinib can shrink tumors or stop the cancer from growing. About 100 participants will take the drug and…

This study tests a treatment called tabelecleucel for people who develop a rare, virus-related cancer after an organ or stem cell transplant and whose cancer did not respond to standard therapy. The treatment uses specially matched immune cells to fight the cancer. About 115 part…

This study tests a drug called entrectinib, already approved for certain lung and solid tumors, in people with rare cancers that have a specific genetic change called ROS1 fusion. About 30 adults, teens, and children with these rare cancers will receive the drug. Researchers will…

This study tests alectinib, a drug already approved for some lung cancers, in patients with rare cancers that have an ALK gene change. About 30 adults and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops them from growing. The goal is…

This study is testing whether a stem cell transplant from a healthy donor can safely treat people with severe immune system problems. Participants (ages 4-75) receive chemotherapy and then donor stem cells, followed by a hospital stay and years of monitoring. The goal is to see i…

This early-stage study tests a new gene therapy called KLN-1010 for people with multiple myeloma that has returned or not responded to treatment. Instead of removing cells, modifying them in a lab, and putting them back, this therapy aims to create cancer-fighting CAR-T cells dir…

This trial tests a drug called atezolizumab, already approved for some cancers, in people with rare cancers that have high numbers of genetic mutations or specific DNA repair problems. About 30 adults and children with these rare tumor types will receive the drug. The main goal i…

This study tests an 8-week virtual rehabilitation program (CaRE@Home) for adults who have finished treatment for breast, colorectal, head and neck cancer, or lymphoma. The goal is to see if the program reduces disability and improves physical function, anxiety, and quality of lif…

This study looks at blood cancer cells from 250 patients to understand which drugs might work best. Researchers will test many approved and experimental drugs on these cells in the lab. The goal is to find new treatment targets and match them to each patient's cancer type. This i…

This study is collecting blood, bone marrow, and tissue samples from over 1,000 people with blood cancers like leukemia and myeloma. Researchers will use advanced lab techniques to find unique markers (biomarkers) for each cancer type. The goal is to better understand these disea…